8/10/2022 8:12:46 AM
Outlook Therapeutics Q3 Loss Per Share $0.08 Vs Loss $0.07 Last Year
3/31/2022 8:13:33 AM
Outlook Therapeutics Submits BLA To FDA For ONS-5010 For Wet Age-related Macular Degeneration
2/14/2022 8:15:29 AM
Outlook Therapeutics Says Remains On Track To Submit FDA BLA For First Ophthalmic Formulation Of Bevacizumab
9/28/2021 8:12:59 AM
Outlook Therapeutics Reports New Positive 12-Month Safety Data From Pivotal Phase 3 NORSE TWO Trial
9/13/2021 8:26:31 AM
Outlook Therapeutics Presents Positive NORSE THREE Safety Data For ONS-5010/LYTENAVA At EURETINA 2021 Medical Conference
5/14/2021 8:13:51 AM
Outlook Therapeutics Q2 Net Loss Attributable $13.1 Mln Or $0.09/Shr Vs Loss $17.5 Mln Or $0.36/Shr Year-ago
3/31/2021 8:29:18 AM
Outlook Therapeutics Reports Positive Safety Profile From NORSE THREE Open-Label Safety Study For ONS-5010 / LYTENAVA
1/29/2021 12:38:37 AM
Outlook Therapeutics Increase Size Of Public Offering And Purchase On Firm Commitment Basis 35 Mln Shares At $1/Shr